Health3 months ago
Pfizer Reports Patient Death in Hemophilia Trial for Hympavzi
Pfizer announced on Tuesday that a participant in a long-term extension trial for its hemophilia therapy, Hympavzi (chemical name: marstacimab), has died following serious adverse events....
